1. Home
  2. LIXT vs SDST Comparison

LIXT vs SDST Comparison

Compare LIXT & SDST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

HOLD

Current Price

$7.00

Market Cap

26.5M

Sector

Health Care

ML Signal

HOLD

Logo Stardust Power Inc.

SDST

Stardust Power Inc.

HOLD

Current Price

$2.03

Market Cap

23.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
LIXT
SDST
Founded
2005
2022
Country
United States
United States
Employees
3
10
Industry
Biotechnology: Pharmaceutical Preparations
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
26.5M
23.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LIXT
SDST
Price
$7.00
$2.03
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
140.9K
139.9K
Earning Date
05-08-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.64
$0.14
52 Week High
$7.50
$7.67

Technical Indicators

Market Signals
Indicator
LIXT
SDST
Relative Strength Index (RSI) 67.55 39.01
Support Level $2.92 $2.01
Resistance Level N/A $2.85
Average True Range (ATR) 0.82 0.25
MACD 0.07 -0.00
Stochastic Oscillator 82.94 16.46

Price Performance

Historical Comparison
LIXT
SDST

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

About SDST Stardust Power Inc.

Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).

Share on Social Networks: